Stocks
Moderna's Cancer Vaccine Breakthrough Gives mRNA Technology New Lease on Life
The mRNA technology that made Moderna and BioNTech's COVID-19 vaccines possible is getting a boost in cancer vaccine development, thanks to recent clinical successes.
After facing criticism and skepticism during the pandemic, researchers are now seeing renewed interest in mRNA-based cancer treatments.
A recent Phase 3 trial by Moderna and Merck for a personalized mRNA vaccine in melanoma has shown positive results, giving the field a much-needed boost.
Experts say this could pave the way for more investment and development in cancer vaccines, which could potentially shift the way many cancers are treated to include vaccination.